Informazioni sul dominio e sul sito Web:
idarucizumab.it
Nome del dominio - idarucizumab.it
Titolo del sito - idarucizumab.it
Domain idarucizumab.it viene reindirizzato a https://www.boehringer-ingelheim.com
Posizione GEO del sito
Posizione Paese - France
Fornitore - Nameshield SAS
Site Logo
indirizzo IP:
Server dei nomi di dominio:
ns3.nameshield.net ns2.observatoiredesmarques.fr obs.ns1.fr
Tutti i record:
☆ idarucizumab.it. 21600 IN TXT "v=spf1 include:_spf.boehringer-ingelheim.com -all"
☆ idarucizumab.it. 21600 IN A 81.92.80.55
☆ idarucizumab.it. 21600 IN A 81.92.80.56
☆ idarucizumab.it. 21600 IN NS obs.ns1.fr.
☆ idarucizumab.it. 21600 IN NS ns3.nameshield.net.
☆ idarucizumab.it. 21600 IN NS ns2.observatoiredesmarques.fr.
☆ idarucizumab.it. 21600 IN SOA obs.ns1.fr. technical.nameshield.net. 2023012318 28800 7200 604800 7200
Brief facts about idarucizumab:
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran. Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes. It was approved for medical use in the United States and in the European Union in 2015.
© DMS 2011-